SEC. 778. For purposes of applying the Federal Food Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), Hawaii grown or produced coffee shall contain at least 51 percent of coffee grown in Kona, Kau, Maui, Oahu, Kauai, or other areas of the State of Hawaii: *Provided,* That based on the region it is produced or grown, the common or usual names shall be Kona Coffee, Kau Coffee, Maui Coffee, Oahu Coffee, Kauai Coffee, or Hawaii Coffee.

SEC. 779. None of the funds made available for any department or agency in this or any other appropriations Acts, including prior year Acts, shall be used to close Natural Resources Conservation Service or Rural Development mission area field offices or to permanently relocate any field-based employees of those agencies that would result in an office with two or fewer employees without prior notification and approval of the Committees on Appropriations of both Houses of Congress.

SEC. 780. No funds appropriated by this Act may be used to administer or enforce the "Requirements for Additional Traceability Records for Certain Foods", published on November 21, 2022 (87 Fed. Reg. 70910), or any other rule promulgated in accordance with section 204 of the FDA Food Safety Modernization Act (21 U.S.C. 2223), prior to July 20, 2028. Further, the U.S. Food and Drug Administration shall:

(1) Engage quarterly with the regulated entities, including farms, restaurants, retail food establishments, and warehouses distributing to retail food establishments and restaurants, to identify and implement, as appropriate, additional flexibilities for satisfying the rule's lot-level tracking requirement, as appropriate, such that regulated entities can comply with the November 21, 2022, rule consistent with section 204(d)(1)(L)(iii), which prohibits the agency from requiring product tracking to the case level.

(2) Within 180 days of enactment of this Act, the Food and Drug Administration is directed to provide industry stakeholders with recommendations for these additional flexibilities satisfying the rule's lot-level tracking requirement, as appropriate.

(3) The FDA shall provide assistance to industry regarding how to handle food waste recovery, reclamation, intra-company transfers, customer returns under the rule and initiate a series of hypothetical data intake exercises to test the capabilities of the FDA's Product Tracing System and, upon request and as resources allow, the covered entity systems and identify any technical difficulties prior to full implementation.

SEC. 781. Effective 365 days after the enactment of this Act, Section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o) is amended—

(1) by redesignating paragraphs (2) through (6) as paragraphs (4) through (8), respectively; and

(2) by striking paragraph (1) and inserting the following: "(1) HEMP.—

"(A) IN GENERAL.—The term 'hemp' means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent on a dry weight basis.

"(B) INCLUSION.—Such term includes industrial hemp.
"(C) EXCLUSIONS.—Such term does not include—
"(i) any viable seeds from a Cannabis sativa L. plant that exceeds a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of 0.3 percent in the plant on a dry weight basis; or
"(ii) any intermediate hemp-derived cannabinoid products containing—
"(I) cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant;
"(II) cannabinoids that—
"(aa) are capable of being naturally produced by a Cannabis sativa L. plant; and
"(bb) were synthesized or manufactured outside the plant; or
"(III) more than 0.3 percent combined total of—
"(aa) total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and
"(bb) any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services); or
"(iii) any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use; or
"(iv) any final hemp-derived cannabinoid products containing—
"(I) cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant;
"(II) cannabinoids that—
"(aa) are capable of being naturally produced by a Cannabis sativa L. plant; and
"(bb) were synthesized or manufactured outside the plant; or
"(III) greater than 0.4 milligrams combined total per container of—
"(aa) total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and
"(bb) any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).

"(2) INDUSTRIAL HEMP.—The term 'industrial hemp' means hemp—
"(A) grown for the use of the stalk of the plant, fiber produced from such a stalk, or any other non-cannabinoid derivative, mixture, preparation, or manufacture of such a stalk;
"(B) grown for the use of the whole grain, oil, cake, nut, hull, or any other non-cannabinoid compound, derivative, mixture, preparation, or manufacture of the seeds of such plant;

"(C) grown for purposes of producing microgreens or other edible hemp leaf products intended for human consumption that are derived from an immature hemp plant that is grown from seeds that do not exceed the threshold for total tetrahydrocannabinols concentration specified in paragraph (1)(C)(i);

"(D) that is a plant that does not enter the stream of commerce and is intended to support hemp research at an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) or an independent research institute; or

"(E) grown for the use of a viable seed of the plant produced solely for the production or manufacture of any material described in subparagraphs (A) through (D).

"(3) HEMP-DERIVED CANNABINOID PRODUCT.—

"(A) IN GENERAL.—The term 'hemp-derived cannabinoid product' means any intermediate or final product derived from hemp (other than industrial hemp), that—

"(i) contains cannabinoids in any form; and

"(ii) is intended for human or animal use through any means of application or administration, such as inhalation, ingestion, or topical application.

"(B) The term 'intermediate hemp-derived cannabinoid product' means a hemp-derived cannabinoid product which—

"(i) is not yet in the final form or preparation marketed or intended to be used or consumed by a human or animal; or

"(ii) is a powder, liquid, tablet, oil, or other product form which is intended or marketed to be mixed, dissolved, formulated, or otherwise added to or prepared with or into any other substance prior to administration or consumption.

"(C) The term 'container' means the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge.

"(D) The term container excludes bulk shipping containers or outer wrappings that are not essential for the final retail delivery or sale to an end consumer for personal or household use.

"(E) EXCLUSION.—Such term does not include a drug that is the subject of an application approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).".

(3) Within 90 days of the enactment of this act, the Food and Drug Administration, in consultation with other relevant Federal agencies, shall publish—

(A) a list of all cannabinoids known to FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature;

(B) a list of all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant;

(C) a list of all other know cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids; and

(D) additional information and specificity about the term "container", as defined in paragraph (3)(C).

SEC. 782. In addition to amounts otherwise made available, there is hereby appropriated $2,000,000, to remain available until expended, for the Meat and Poultry Processing Expansion Program established pursuant to section 1001(b)(4) of the American Rescue Plan Act of 2021 (Public Law 117–2) to award grants to processors of invasive, wild-caught catfish.

SEC. 783. (a) During the period beginning on the effective date of the final rule entitled "Food Labeling: Nutrient Content Claims; Definition of Term 'Healthy'" published in the Federal Register by the Food and Drug Administration on December 27, 2024 (89 Fed. Reg. 106064 et seq.) and ending on the compliance date specified in such final rule (referred to in this section as the "compliance period"), a manufacturer may also continue to comply with the requirements in effect on the day before such effective date relating to an implied nutrient content claim of "healthy" made with respect to a food.

(b) In the case of a food that bears labeling making an implied nutrition content claim that the food is "healthy" during the compliance period, the manufacturer of the food shall not be directly or indirectly subject to any State law requirement relating to labeling making an implied nutrient content claim that a food is "healthy" during such period that is not identical to either—

(1) the Federal requirements for labeling to make an implied nutrition content claim that a food is "healthy" that were in effect on the day before the effective date of such final rule; or

(2) the updated Federal requirements specified in the final rule for such a claim.

SEC. 784. Of the unobligated balances available in the Department of the Treasury, Treasury Forfeiture Fund, established by section 9703 of title 31, United States Code, $350,000,000 shall be permanently rescinded not later than September 30, 2026.

SEC. 785. The Commissioner of the Food and Drug Administration shall develop a report to determine the cost and any implications associated with efforts to issue a proposed rule and implement FDA guidance and enforcement for setting standards for pet and animal food labeling and ingredient regulation: *Provided*, That the report shall—

(1) cover intent for harmonization across state and Federal regulatory bodies for pet and animal food labeling and ingredients;

(2) include timelines for developing guidelines, proposed regulations, resource and personnel needs to implement such standards, and where FDA would need additional authority to implement any proposed changes; and

be submitted to the House and Senate Committees on Appropriations within 120 days of enactment of this Act.

SEC. 786. Any remaining unobligated balances from amounts made available by section 743 of division A of the Consolidated Appropriations Act, 2017 (Public Law 115–31) may be used, in addition to any funds otherwise made available for such purposes,